HOXA9 and lung carcinoma: In conclusion, we found that the aberrant promotor methylation of OncoMe (SHOX2, RASSF1A, SEPTIN9 and HOXA9) is a cancer-specific alteration and may be a valuable marker to aid in the differentiation of MPE, even not limited to lung cancer.